C2CD5

C2CD5 (CDP138/KIAA0528) is a calcium- and lipid-binding C2-domain protein that regulates regulated membrane trafficking and vesicle fusion across metabolic and neuronal tissues (PMID:21907143, PMID:29378832). In adipocytes it acts as a direct Akt2 substrate: its purified C2 domain binds Ca²⁺ and lipid membranes, Akt2 phosphorylates it at S197, and both Ca²⁺-binding and S197 phosphorylation are required for insulin-stimulated fusion of GLUT4 vesicles with the plasma membrane (PMID:21907143). A second mechanistic role centers on intracellular organelle transport, where C2CD5 forms a stable complex with CDK5 and FIBP and, together with 14-3-3ε, promotes CDK5-mediated NudEL phosphorylation to increase dynein–NudEL interaction and dynein force production for movement of lipid droplets, lysosomes, and mitochondria (PMID:25096995, PMID:30651536). In the nervous system C2CD5 governs sympathetic catecholamine output: it is expressed in adrenal medulla and DBH⁺ sympathetic neurons, and its loss reduces norepinephrine secretion and impairs cold-induced adrenergic signaling, fat browning, energy expenditure, and insulin sensitivity, defects mitigated by norepinephrine supplementation (PMID:29378832, PMID:42006349). In hypothalamic neurons C2CD5 promotes MC4R endocytosis through its C2 domain and is required for proper mitochondrial trafficking, ultrastructure, and respiration (PMID:31666192, PMID:34034255). C2CD5 is stabilized by the deubiquitinase USP5, which acts on a C2CD5–FIBP–CDK5 complex to activate PI3K/AKT/mTOR signaling and HIF-1α–driven glycolysis in acute myeloid leukemia (PMID:41344512).

1. 2011 High

   Established C2CD5 as an Akt2 effector linking insulin signaling to vesicle fusion, answering how phosphoinositide-3-kinase output is converted into membrane fusion of glucose transporter vesicles.

   Evidence Quantitative phosphoproteomics, purified C2-domain Ca²⁺/lipid binding assays, S197 and Ca²⁺-site mutagenesis, RNAi, and live-cell GLUT4 fusion imaging in adipocytes

   PMID:21907143

   Open questions at the time

   • Identity of the fusion machinery (SNAREs/tethers) C2CD5 engages not defined
   • Structural basis of Ca²⁺/lipid binding by the C2 domain not resolved
2. 2014 Medium

   Defined C2CD5 as a structural component of a CDK5 complex, showing it is not solely an adipocyte trafficking protein but an assembly factor for a kinase complex relevant to cell proliferation and migration.

   Evidence Affinity purification/MS with SAINT analysis, reciprocal co-IP, and RNAi proliferation/migration assays in breast cancer cells

   PMID:25096995

   Open questions at the time

   • Molecular role of C2CD5 within the complex (scaffold vs. cofactor) not mechanistically dissected here
   • Substrates downstream of the complex not identified at this stage
3. 2017 Medium

   Connected C2CD5 to TGF-β/Smad signaling via GDF15, extending its functional reach to a transcriptional/secreted-factor axis controlling cancer cell phenotypes.

   Evidence RNAi knockdown, GDF15 rescue, Smad signaling, migration/invasion, and radiosensitivity assays in lung cancer cells

   PMID:28880265

   Open questions at the time

   • Direct mechanism by which C2CD5 upregulates GDF15 unknown
   • Rescue was only partial, leaving additional effectors unaccounted for
4. 2018 High

   Established an in vivo physiological role for C2CD5 in sympathetic/adrenal catecholamine secretion controlling fat browning and insulin sensitivity, moving beyond cell-based trafficking assays.

   Evidence Whole-body knockout mice, catecholamine measurement, cAMP/HSL phosphorylation readouts, cold challenge, and tyrosine hydroxylase colocalization

   PMID:29378832

   Open questions at the time

   • Molecular step in catecholamine vesicle secretion controlled by C2CD5 not pinpointed
   • Whole-body KO cannot exclude contributions from non-neuronal tissues
5. 2019 High

   Mechanistically resolved the CDK5 complex function, showing C2CD5 acts as a CDK5 cofactor driving NudEL phosphorylation and dynein force adaptation for organelle transport.

   Evidence Single-molecule dynein force measurements, RNAi epistasis of C2CD5/CDK5/14-3-3ε, NudEL phosphorylation, and lipid droplet/lysosome/mitochondria transport assays in COS-1 cells

   PMID:30651536

   Open questions at the time

   • How C2CD5's C2/lipid-binding activity contributes to this cytosolic kinase function not clarified
   • Direct contact between C2CD5 and CDK5 active site not structurally defined
6. 2019 Medium

   Identified a hypothalamic neuronal role in MC4R endocytosis, linking C2CD5 trafficking activity to central melanocortin signaling and energy balance.

   Evidence Whole-body KO mice, antibody-feeding endocytosis assay with C2-domain deletion mutant, flow cytometry, EM, in vivo MTII injection, and RNAscope

   PMID:31666192

   Open questions at the time

   • Specific endocytic machinery components C2CD5 binds not named
   • Whether MC4R endocytosis defect is direct or secondary to broader trafficking loss unresolved
7. 2021 Medium

   Showed C2CD5 is required for mitochondrial trafficking, morphology, and respiration in hypothalamic neurons, tying its transport function to neuronal bioenergetics.

   Evidence Primary hypothalamic neuron cultures from KO mice, EM, live-cell imaging, and oxygen consumption assays

   PMID:34034255

   Open questions at the time

   • Causal ordering between mitochondrial dysfunction and MC4R trafficking defect not established
   • Whether mitochondrial phenotype reflects the dynein/CDK5 transport pathway not tested directly
8. 2025 Medium

   Revealed post-translational control of C2CD5 by USP5 deubiquitination, coupling C2CD5 stability to PI3K/AKT/mTOR and HIF-1α–driven glycolysis in leukemia.

   Evidence Co-IP/MS, USP5 knockdown, deubiquitination assays, pathway readouts, and an in vivo AML mouse model

   PMID:41344512

   Open questions at the time

   • Ubiquitin ligase opposing USP5 on C2CD5 not identified
   • Direct mechanism by which stabilized C2CD5 activates PI3K/AKT/mTOR not defined
9. 2026 Medium

   Refined the sympathetic role using cell-type-specific deletion, placing C2CD5 upstream of norepinephrine secretion in DBH⁺ neurons to control thermogenesis and adiposity.

   Evidence DBH-specific conditional KO mice, NE secretion measurements, metabolic cage analysis, and NE supplementation rescue

   PMID:42006349

   Open questions at the time

   • Molecular step in NE vesicle secretion governed by C2CD5 not defined
   • Connection to the C2CD5 GLUT4/dynein mechanisms in this neuronal context not established

• How a single C2-domain trafficking protein mechanistically unifies Akt2-dependent GLUT4 fusion, CDK5-dependent dynein force adaptation, and regulated catecholamine secretion remains unresolved.
• No structural model of C2CD5 or its complexes
• Whether the C2/Ca²⁺-lipid module is used in all these contexts is untested
• The direct fusion/secretion machinery C2CD5 engages is not identified